Literature DB >> 3679541

Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters.

P H Kim1, J P Iaconis, R D Rolfe.   

Abstract

In this investigation, the role of antibodies against Clostridium difficile toxins A and B in protecting hamsters against C. difficile-associated ileocecitis was examined. We also studied the transfer of protection against C. difficile-associated intestinal disease from immunized female hamsters to their infants. Adult female hamsters immunized parenterally with toxoid A or a mixture containing both toxoids A and B were protected against clindamycin-induced C. difficile-associated fatal ileocecitis. On the other hand, hamsters immunized with toxoid B or a broth filtrate from a nontoxigenic strain of C. difficile were not protected against C. difficile-induced ileocecitis. Antibody against the immunizing toxoid could be demonstrated in both the serum and the cecal contents of hamsters. Some infant hamsters from mothers immunized with toxoid A or AB were protected against C. difficile-associated ileocecitis, while infant hamsters from mothers immunized with toxoid B or a nontoxigenic broth filtrate were not protected against disease. Neutralizing antibodies to toxins A and B could be demonstrated in both maternal milk and serum, as well as in infant serum and intestinal contents. Foster-mothering experiments demonstrated that maternal protection of infants against C. difficile-associated ileocecitis was transferred to infant hamsters through breast milk. These results suggest that toxin A may play a more important role in the pathogenesis of C. difficile-associated ileocecitis in hamsters than toxin B. Furthermore, variations in the severity of C. difficile-associated illness in infants and adults may reflect the lack or presence of passively or actively acquired immunity against C. difficile toxins.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3679541      PMCID: PMC260017          DOI: 10.1128/iai.55.12.2984-2992.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 2.  Host resistance factors in human milk.

Authors:  A S Goldman; C W Smith
Journal:  J Pediatr       Date:  1973-06       Impact factor: 4.406

3.  Cessation of uptake of macromolecules by neonatal guinea pig, hamster and rabbit intestinal epithelium (closure) and transport into blood.

Authors:  J G Lecce; C W Broughton
Journal:  J Nutr       Date:  1973-05       Impact factor: 4.798

4.  Protection against enteric bacterial infection by secretory IgA antibodies.

Authors:  E S Fubara; R Freter
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

5.  Production of Clostridium difficile antitoxin.

Authors:  M Ehrich; R L Van Tassell; J M Libby; T D Wilkins
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

6.  Recovery of Clostridium difficile from children.

Authors:  E Holst; I Helin; P A Mårdh
Journal:  Scand J Infect Dis       Date:  1981

7.  Selective and differential medium for isolation of Clostridium difficile.

Authors:  W L George; V L Sutter; D Citron; S M Finegold
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

Review 8.  Antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett
Journal:  Rev Infect Dis       Date:  1979 May-Jun

9.  Purification and characterization of Clostridium difficile toxin.

Authors:  R D Rolfe; S M Finegold
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

10.  Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.

Authors:  R Viscidi; S Willey; J G Bartlett
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

View more
  49 in total

Review 1.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

2.  The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B.

Authors:  M H Souza; A A Melo-Filho; M F Rocha; D M Lyerly; F Q Cunha; A A Lima; R A Ribeiro
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 3.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 4.  Pathogenesis and treatment of Clostridium difficile infection.

Authors:  I Tonna; P D Welsby
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

Review 5.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Clostridium difficile toxin A induces a specific antisecretory factor which protects against intestinal mucosal damage.

Authors:  J Torres; E Jennische; S Lange; I Lönnroth
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

7.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

Review 8.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

9.  Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.

Authors:  J F Torres; D M Lyerly; J E Hill; T P Monath
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

Authors:  M Warny; J P Vaerman; V Avesani; M Delmée
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.